Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biosig Technologies (BSGM)

Biosig Technologies (BSGM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,732
  • Shares Outstanding, K 29,648
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,050 K
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.20
Trade BSGM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +399,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.55 +21.76%
on 10/02/20
8.76 -36.72%
on 09/21/20
-3.06 (-35.58%)
since 09/18/20
3-Month
4.55 +21.76%
on 10/02/20
9.77 -43.30%
on 08/03/20
-2.75 (-33.17%)
since 07/17/20
52-Week
2.36 +134.75%
on 03/18/20
12.43 -55.43%
on 05/12/20
-1.44 (-20.63%)
since 10/18/19

Most Recent Stories

More News
Sales Grow as Public Opinion on PPE Shifts

, /PRNewswire/ -- The economy shows signs of recovery, but fears that the pandemic will hit with a second wave may cause further devastations in the months to come. Besides the research necessary to develop...

OPK : 4.74 (+10.23%)
OPTI : 0.0290 (+16.00%)
DVAX : 4.37 (-1.58%)
VXRT : 5.79 (-4.77%)
BSGM : 5.55 (-0.72%)
Sorrento & ViralClear Explore Combination Coronavirus Treatments

Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.

REGN : 585.44 (-2.38%)
GILD : 60.77 (-1.98%)
BSGM : 5.55 (-0.72%)
SRNE : 9.12 (-1.94%)
SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19

EQNX::TICKER_START (NASDAQ:BSGM),(NASDAQ:SRNE), EQNX::TICKER_END

BSGM : 5.55 (-0.72%)
SRNE : 9.12 (-1.94%)
ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution

EQNX::TICKER_START (NASDAQ:BSGM), EQNX::TICKER_END

BSGM : 5.55 (-0.72%)
Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

EQNX::TICKER_START (NASDAQ:BSGM),(NASDAQ:BSGM), EQNX::TICKER_END

BSGM : 5.55 (-0.72%)
Global Electrophysiology Devices Market Could Exceed $12.2 Billion By 2026

, /PRNewswire/ -- In the world of cardiovascular devices the electrophysiology segment is poised to have substantial growth according to various industry reports. It has recently become of great interest...

BSGM : 5.55 (-0.72%)
IRTC : 230.29 (-2.35%)
AFIB : 25.72 (-1.72%)
JNJ : 146.72 (-0.93%)
BSX : 38.24 (-0.52%)
BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology's 'ESC Congress 2020'

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity...

BSGM : 5.55 (-0.72%)
BioSig Announces Abstract Acceptance to Computing in Cardiology 2020

EQNX::TICKER_START (NASDAQ:BSGM), EQNX::TICKER_END

BSGM : 5.55 (-0.72%)
Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

EQNX::TICKER_START (NASDAQ:BSGM), EQNX::TICKER_END

BSGM : 5.55 (-0.72%)
ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

EQNX::TICKER_START (NASDAQ:BSGM), EQNX::TICKER_END

BSGM : 5.55 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company's first product, PURE EP(tm) System is a computerized system intended for...

See More

Key Turning Points

2nd Resistance Point 6.02
1st Resistance Point 5.81
Last Price 5.55
1st Support Level 5.47
2nd Support Level 5.34

See More

52-Week High 12.43
Fibonacci 61.8% 8.58
Fibonacci 50% 7.39
Fibonacci 38.2% 6.21
Last Price 5.55
52-Week Low 2.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar